Latest news with #OSEImmunotherapeuticsSA
Yahoo
6 days ago
- Business
- Yahoo
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
Figure_1 OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipeline through lusvertikimab development, leveraging a new predictive biomarker. Leads a new era in cancer vaccines with Tedopi® on track for registration. Drives company transformation through responsible governance: international development, rigorous financial planning and clinical execution. NANTES, France – June 4th, 2025, 8:00 am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today outlined the company's ambition for long-term growth and sustainable shareholder and societal value. Nicolas Poirier, CEO of OSE Immunotherapeutics notes: "OSE's grounding in solid science, our collaborative approach and a skilled workforce have resulted in a transformative two years, progressing our mission to bring breakthrough immunotherapies to the clinic. We are proud of our accomplishments, particularly delivering positive results for our lead assets, lusvertikimab and Tedopi®, which hold the potential to redefine standards of care across multiple diseases in I&I and I/O. We also secured new partnerships for our preclinical programs and significantly strengthened our financial position with over €90 million in new non-dilutive funding. OSE is positioned among Europe's leading biotechs. Now, it's time to build a more ambitious international company and unlock greater long-term value for all stakeholders.' OSE Immunotherapeutics' Board of Directors, led by Chairman, Didier Hoch, commented: 'Under the joint leadership of the Board and Executive Team, OSE has shown resilience and growth in a competitive biotech landscape. The company is entering a decisive phase. Our strategy is built on three pillars: maintaining scientific leadership, expanding strategic alliances, and ensuring disciplined financial management for sustainable growth. To achieve this, the company will explore various options, including business development, strategic alliances, international investments, and a potential Nasdaq listing. We are shaping the future by building an ambitious international biotech, driven by innovation creating lasting value for patients, employees, and shareholders.' New predictive biomarker with potential to revolutionize UC treatment, an emerging value lever for lusvertikimab Despite intensive therapeutic research in IBD, only 25–30% of UC patients currently achieve clinical remission, and this limitation—commonly referred to as the therapeutic ceiling (Vieujean S. Nature Reviews Gastroenterology, 2025)—persists across all approved therapies and drug classes in late-stage development. OSE research and translational teams, in collaboration with foundational model specialists, have identified a predictive biomarker that can isolate a subpopulation of patients (~30%) and offer significantly enhanced treatment outcomes, potentially achieving clinical remission rates exceeding 50%. This biomarker-driven approach was developed using advanced AI and transfer learning. The model was trained on multimodal data from millions of chronic inflammatory disease patients and refined with data from CoTikiS Phase 2 study. Importantly, biomarker-negative patients showed 0% clinical remission in this dataset, indicating no loss of treatment opportunity when prioritizing treatment based on biomarker status. This precision medicine approach could position lusvertikimab as a first-line therapy for the biomarker-positive population; a potential addressable market opportunity exceeding $3 billion across seven major markets. Next steps include prospective validation of this predictive biomarker through stratification in future clinical trials. Nicolas Poirier details: 'Our comprehensive dataset for lusvertikimab, with its novel upstream mechanism demonstrating clinical efficacy and good safety supports development in UC and other autoimmune diseases. The identification of a predictive biomarker is a breakthrough, suggesting that around 30% of UC patients could achieve remission rates over 50%. This reinforces lusvertikimab's potential as a monotherapy in UC and acts as an additional catalyst to accelerate development. We are designing a Phase 2b program to demonstrate efficacy by 2027, establish the dose for registrational studies, explore a subcutaneous formulation, and validate the predictive biomarker.' Commenting on OSE's progress in Tedopi, Nicolas Poirier adds: 'Earlier this week, we shared our progress with Tedopi® (link to press release). To summarize, our pivotal Phase 3 program in NSCLC with Tedopi® is progressing well, keeping us in the race to register the first therapeutic cancer vaccine. Enrolment is advancing across 144 clinical sites in Europe and North America and is on track to complete in the second half of 2026. The data readout is expected in 2027. The recent positive results in pancreatic cancer highlight the growing momentum behind therapeutic cancer vaccines. We are looking forward to additional Phase 2 readouts in combination with anti-PD1 from our ovarian and lung cancer trials in 2026.' Nicolas Poirier concludes: 'OSE is at the forefront of transformative scientific breakthroughs in areas of critical unmet medical need. I am convinced that the company is at a turning-point, with a clear international trajectory toward value creation and long-term impact. With strong science, strategic focus, and a robust diversified pipeline, OSE is uniquely positioned to deliver meaningful returns for shareholders—while transforming outcomes for patients worldwide.' DOCUMENTS MADE AVAILABLE TO SHAREHOLDERSThe convening brochure for the combined shareholders' meeting of June 25, 2025, now available on the Company's website ( is an essential tool for understanding the strategy pursued by the Board of Directors, informing shareholders and facilitating their voting decision. The related press release, presenting the context of the combined shareholders' meeting and the Board's position on all resolutions, is also available here: ABOUT COTIKIS The CoTikiS study, a 50-week randomized, double-blind, placebo-controlled trial, included a 10-week induction period evaluating two doses (450 mg or 850 mg) of lusvertikimab versus placebo; followed by a 24-week open label extension (OLE) with 850 mg infusions every four weeks; and a 16-week safety follow-up. Findings from the induction phase, presented at the 2025 ECCO congress, showed both doses met the primary efficacy endpoint (improvement in Modified Mayo Score at Week 10) and demonstrated significant results on secondary endpoints. The study highlights lusvertikimab's potential as a first-in-class monotherapy with a novel mechanism of action in the treatment of chronic and inflammatory diseases. Clinical and preclinical data were presented at ECCO 2025 and Digestive Disease Week (DDW) in May 2025, showing high rates of clinical and endoscopic remission, histological improvement and Histo-Endoscopic Mucosal Improvement (HEMI) with a favorable safety profile. Early efficacy signals in both biologic-naïve and experienced populations suggest rapid onset of effect, indicating potential as a first-line biologic or for patients resistant to anti-TNF and anti-IL-12/23 therapies. OLE data shows over 90% of UC patients who achieved a clinical response after 10 weeks maintained symptomatic remission for an additional 24 weeks, with 61% of those not in remission after 10 weeks achieving it after a further 24 weeks on the 850 mg dose. Lusvertikimab was well tolerated over the extended treatment period. ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachments Figure_1 EN_250604_Bold Strategic Vision press release_vf3
Business Insider
24-05-2025
- Business
- Business Insider
Kepler Capital Keeps Their Buy Rating on OSE Immunotherapeutics SA (6OP)
Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on OSE Immunotherapeutics SA (6OP – Research Report) on May 22 and set a price target of €12.50. The company's shares closed last Wednesday at €5.93. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Pauillac is ranked #1271 out of 9536 analysts. OSE Immunotherapeutics SA has an analyst consensus of Moderate Buy, with a price target consensus of €13.25, a 123.44% upside from current levels. In a report released on May 7, H.C. Wainwright also maintained a Buy rating on the stock with a €14.00 price target.
Yahoo
05-05-2025
- Health
- Yahoo
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period. Oral presentation at DDW 2025 of clinical data from the anti-IL-7R mAb Lusvertikimab open-label extension of the phase 2 CoTikiS study in ulcerative colitis.1,2 Full clinical data package for study demonstrates potential of a first-in-class monotherapy with a novel mechanism of action in chronic and inflammatory diseases. NANTES, France – May 5, 2025, 6:30 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announced that over >90% of people living with ulcerative colitis (UC) who achieved a clinical response after 10 weeks of treatment with Lusvertikimab maintained symptomatic remission for an additional 24 weeks. Of the participants who did not reach symptomatic remission in the first 10 weeks of treatment with either dose of Lusvertikimab, 61% had achieved remission after a further 24 weeks on the 850 mg dose. Lusvertikimab was well tolerated over the 24-week extended treatment period.1 These findings from the open-label extension (OLE) of the Phase 2 CoTikiS study of the anti-IL-7 receptor monoclonal antibody Lusvertikimab in UC,2 were presented at Digestive Disease Week in San Diego (May 3 – 6, 2025).1 These build on results from the earlier induction phase presented at the ECCO 2025 congress in February.3 Sonya Montgomery, Chief Development Officer of OSE Immunotherapeutics, commented: 'These new data provide insights into the longer-term benefits and safety of Lusvertikimab in UC, with 89% of patients continuing into the OLE period and 87% completing it. More than 90% of Lusvertikimab patients in symptomatic remission following induction reported a durable response to treatment, and Lusvertikimab also demonstrated very good safety and tolerability over the course of the study, which included 24 weeks on the high dose for all patients. 'We also observed an increase in symptomatic remission rates across groups in the OLE, with the 850 mg induction phase dose group showing this deepening of effect after one additional dose. The OLE data support the potential of Lusvertikimab as a monotherapy with a positive impact on symptom management and patient quality of life.' Arnaud Bourreille, Associate Professor in Gastro-Enterology at CHU Nantes and principal investigator of the study, commented: 'Despite the broad range of approaches to manage ulcerative colitis, remission of symptoms can be hard to reach, with only 25-30% of people typically able to achieve and maintain remission of symptoms on any one treatment.4,5 For people living with ulcerative colitis, these findings are an important step towards challenging this therapeutic ceiling.' Findings from the OLE period, extending from Week 10 to Week 34, complete the CoTikiS dataset which provides a compelling Phase 2 efficacy and safety data package for Lusvertikimab in UC. Sonya Montgomery added: 'The complete CoTikiS results give us confidence in Luservtikimab's novel mechanism of action benefiting ulcerative colitis patients, and its potential in other chronic autoimmune and inflammatory diseases where there is a strong biological rationale. The CoTikiS clinical results support progressing Luzvertikimab's development and brings us closer to our goal of delivering a long-acting therapy designed to treat the underlying disease pathophysiology.' OVERVIEW OF COTIKIS EXTENSION PERIOD (OLE) FINDINGS1 Lusvertikimab demonstrated a deepening of treatment response and durable response, with a high rate of symptomatic remission.1 89% of participants entered the OLE period and 87% of them completed the study. Rates of symptomatic remission6 improved for all dose groups in the OLE period, suggesting a deepening of efficacy. For participants who had received the 850 mg dose from the beginning of the study, rates plateaued already after Week 14; rates of symptomatic remission continued to improve through week 26 for the 450 mg induction group (10 weeks of 450 mg, 16 weeks of 850 mg dosing) and through week 34 for the group receiving placebo in the induction phase (10 weeks of placebo, 14 weeks of 850 mg Lusvertikimab). 92% of participants who had achieved symptomatic remission with either dose of Lusvertikimab in the induction period maintained it through the OLE period7 including 100% of those who achieved remission in the 850 mg dose group. 61% of participants who had not achieved symptomatic remission with either dose of Lusvertikimab in the induction period went on to achieve it during the OLE period. 85% of participants who had been in the placebo arm during the induction period went on to achieve symptomatic remission after receiving 850 mg in the OLE period. 82% of participants achieved remission of rectal bleeding by the end of the OLE. Lusvertikimab was well tolerated over a 34-week treatment period, with a good safety profile and without a higher rate or severity of infection. ABOUT THE COTIKIS STUDY1-3 CoTikiS, a randomized, double-blind, placebo-controlled 50-week clinical study,2 consisted of: A 10-week induction period evaluating two doses (450 mg or 850 mg) of Lusvertikimab versus placebo; A 24-week OLE period in which all participants received Lusvertikimab 850 mg infusions every four weeks; and A 16-week safety follow-up period without treatment. Findings from the induction phase of the CoTikiS study were presented in February at the 2025 ECCO congress. Both doses met the primary efficacy endpoint (improvement in Modified Mayo Score at Week 10) and demonstrated statistically significant and clinically meaningful results on secondary clinical, endoscopy and histology endpoints.3 REFERENCES / FOOTNOTES Bourreille A et al., Oral presentation #913, Digestive Disease Week, 5 May 2025, San Diego, USA. Bourreille A et al., J Crohn's & Colitis 2025; 19(1):i71–i72. doi: 10.1093/ecco-jcc/jjae190.0036. EU Clinical Trials Register: CoTikiS study record (2020-001398-59), available via [Accessed May 2025]. Yanofsky R & Rubin DT, J Can. Assoc. Gastroenterology 2025;8(S2):S6–S14, doi: 10.1093/jcag/gwae058. Le Berre C et al. Lancet 2023;402(10401):571–584, doi: 10.1016/S0140-6736(23)00966-2. Symptomatic remission on Mayo patient-reported outcomes 2, PRO2 (stool frequency subscore + rectal bleeding subscore) = 0 or 1 and rectal bleeding subscore = 0. Responders are defined as patients with endoscopic score of 0 or 1 at Week 10. ABOUT DIGESTIVE DISEASE WEEK (DDW)Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases nearly 6,000 abstracts and over 1,000 invited talks on the latest advances in GI research, medicine and technology. More information can be found at ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on LinkedIn. Contacts Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachment EN_250505_DDW Lusvertikimab_FINALSign in to access your portfolio
Yahoo
05-05-2025
- Health
- Yahoo
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab
OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period. Oral presentation at DDW 2025 of clinical data from the anti-IL-7R mAb Lusvertikimab open-label extension of the phase 2 CoTikiS study in ulcerative colitis.1,2 Full clinical data package for study demonstrates potential of a first-in-class monotherapy with a novel mechanism of action in chronic and inflammatory diseases. NANTES, France – May 5, 2025, 6:30 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announced that over >90% of people living with ulcerative colitis (UC) who achieved a clinical response after 10 weeks of treatment with Lusvertikimab maintained symptomatic remission for an additional 24 weeks. Of the participants who did not reach symptomatic remission in the first 10 weeks of treatment with either dose of Lusvertikimab, 61% had achieved remission after a further 24 weeks on the 850 mg dose. Lusvertikimab was well tolerated over the 24-week extended treatment period.1 These findings from the open-label extension (OLE) of the Phase 2 CoTikiS study of the anti-IL-7 receptor monoclonal antibody Lusvertikimab in UC,2 were presented at Digestive Disease Week in San Diego (May 3 – 6, 2025).1 These build on results from the earlier induction phase presented at the ECCO 2025 congress in February.3 Sonya Montgomery, Chief Development Officer of OSE Immunotherapeutics, commented: 'These new data provide insights into the longer-term benefits and safety of Lusvertikimab in UC, with 89% of patients continuing into the OLE period and 87% completing it. More than 90% of Lusvertikimab patients in symptomatic remission following induction reported a durable response to treatment, and Lusvertikimab also demonstrated very good safety and tolerability over the course of the study, which included 24 weeks on the high dose for all patients. 'We also observed an increase in symptomatic remission rates across groups in the OLE, with the 850 mg induction phase dose group showing this deepening of effect after one additional dose. The OLE data support the potential of Lusvertikimab as a monotherapy with a positive impact on symptom management and patient quality of life.' Arnaud Bourreille, Associate Professor in Gastro-Enterology at CHU Nantes and principal investigator of the study, commented: 'Despite the broad range of approaches to manage ulcerative colitis, remission of symptoms can be hard to reach, with only 25-30% of people typically able to achieve and maintain remission of symptoms on any one treatment.4,5 For people living with ulcerative colitis, these findings are an important step towards challenging this therapeutic ceiling.' Findings from the OLE period, extending from Week 10 to Week 34, complete the CoTikiS dataset which provides a compelling Phase 2 efficacy and safety data package for Lusvertikimab in UC. Sonya Montgomery added: 'The complete CoTikiS results give us confidence in Luservtikimab's novel mechanism of action benefiting ulcerative colitis patients, and its potential in other chronic autoimmune and inflammatory diseases where there is a strong biological rationale. The CoTikiS clinical results support progressing Luzvertikimab's development and brings us closer to our goal of delivering a long-acting therapy designed to treat the underlying disease pathophysiology.' OVERVIEW OF COTIKIS EXTENSION PERIOD (OLE) FINDINGS1 Lusvertikimab demonstrated a deepening of treatment response and durable response, with a high rate of symptomatic remission.1 89% of participants entered the OLE period and 87% of them completed the study. Rates of symptomatic remission6 improved for all dose groups in the OLE period, suggesting a deepening of efficacy. For participants who had received the 850 mg dose from the beginning of the study, rates plateaued already after Week 14; rates of symptomatic remission continued to improve through week 26 for the 450 mg induction group (10 weeks of 450 mg, 16 weeks of 850 mg dosing) and through week 34 for the group receiving placebo in the induction phase (10 weeks of placebo, 14 weeks of 850 mg Lusvertikimab). 92% of participants who had achieved symptomatic remission with either dose of Lusvertikimab in the induction period maintained it through the OLE period7 including 100% of those who achieved remission in the 850 mg dose group. 61% of participants who had not achieved symptomatic remission with either dose of Lusvertikimab in the induction period went on to achieve it during the OLE period. 85% of participants who had been in the placebo arm during the induction period went on to achieve symptomatic remission after receiving 850 mg in the OLE period. 82% of participants achieved remission of rectal bleeding by the end of the OLE. Lusvertikimab was well tolerated over a 34-week treatment period, with a good safety profile and without a higher rate or severity of infection. ABOUT THE COTIKIS STUDY1-3 CoTikiS, a randomized, double-blind, placebo-controlled 50-week clinical study,2 consisted of: A 10-week induction period evaluating two doses (450 mg or 850 mg) of Lusvertikimab versus placebo; A 24-week OLE period in which all participants received Lusvertikimab 850 mg infusions every four weeks; and A 16-week safety follow-up period without treatment. Findings from the induction phase of the CoTikiS study were presented in February at the 2025 ECCO congress. Both doses met the primary efficacy endpoint (improvement in Modified Mayo Score at Week 10) and demonstrated statistically significant and clinically meaningful results on secondary clinical, endoscopy and histology endpoints.3 REFERENCES / FOOTNOTES Bourreille A et al., Oral presentation #913, Digestive Disease Week, 5 May 2025, San Diego, USA. Bourreille A et al., J Crohn's & Colitis 2025; 19(1):i71–i72. doi: 10.1093/ecco-jcc/jjae190.0036. EU Clinical Trials Register: CoTikiS study record (2020-001398-59), available via [Accessed May 2025]. Yanofsky R & Rubin DT, J Can. Assoc. Gastroenterology 2025;8(S2):S6–S14, doi: 10.1093/jcag/gwae058. Le Berre C et al. Lancet 2023;402(10401):571–584, doi: 10.1016/S0140-6736(23)00966-2. Symptomatic remission on Mayo patient-reported outcomes 2, PRO2 (stool frequency subscore + rectal bleeding subscore) = 0 or 1 and rectal bleeding subscore = 0. Responders are defined as patients with endoscopic score of 0 or 1 at Week 10. ABOUT DIGESTIVE DISEASE WEEK (DDW)Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 3-6, 2025. The meeting showcases nearly 6,000 abstracts and over 1,000 invited talks on the latest advances in GI research, medicine and technology. More information can be found at ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on LinkedIn. Contacts Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachment EN_250505_DDW Lusvertikimab_FINAL
Yahoo
30-04-2025
- Health
- Yahoo
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response to immune checkpoint. Potential of signature to enhance personalized treatment for patients, regardless of cancer type. NANTES, France – April 30, 2025, 7:30 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today reported on an oral presentation from a research collaboration with the renowned Léon Bérard Cancer Center in Lyon at the American Association for Cancer Research (AACR) Annual Meeting held April 25 – 30, 2025, in Chicago. Immune checkpoint blockade (ICB) therapies, targeting PD-1, PD-L1, and CTLA-4, have revolutionized cancer treatment by helping the immune system recognize and attack cancer cells more effectively. These therapies offer lasting responses and significant survival benefits across various cancers. However, current biomarkers like PD-L1 expression and tumor mutational burden (TMB) are not always reliable. PD-L1 expression can vary within tumors and between patients, making predictions inconsistent. Therefore, more universally applicable biomarkers are needed to predict patient responses and guide treatment decisions. While RNA sequencing has created detailed gene expression signatures (GES) that describe the tumor environment, their use in everyday clinical practice is limited due to their specificity and lack of widespread adoption. The presentation, entitled ' reported on the development and validation of a robust and tumor-agnostic composite gene expression signature (cGES) that can predict overall survival and progression free survival in cancer patients treated with immune checkpoint blockers (e.g. Anti PD-L1, Anti PD-1 and Anti CTLA-4). This signature could be useful in clinical practice to better stratify patients on risk and potentially guide treatment decisions of multiple cancer types. Professor Pierre Saintigny of Université Claude Bernard Lyon 1, Centre Léon Bérard Comprehensive Cancer Center and Team leader Inserm/Inria at Cancer Research Centre of Lyon stated: 'Our collaborative research program validated a composite gene expression signature with a strong potential for stratifying and predicting clinical outcomes more accurately, which could significantly improve personalized treatment in clinical practice for ICB-treated patients, regardless of cancer type. We were very pleased to present the results of our translational research at the AACR conference on this cutting-edge program conducted in collaboration with OSE Immunotherapeutics' teams.' ABOUT THE LÉON BÉRARD CENTERThe Centre Léon Bérard (CLB) is part of the twenty French Comprehensive Cancer Centres in France, providing a global management of cancer patients on a unique area, from diagnosis to treatment and beyond. The Centre is a regional, national and international recognized reference cancer Centre assigned with three essential missions: Care, Research and Education and is willing to continuously improve the quality and accessibility of care for cancer patients. ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on LinkedIn. Contacts Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachment EN_250430_AACR_Oral presentationSign in to access your portfolio
